07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

QPI-1007: Phase IIa started

SBI Biotech’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, sham-controlled, international Phase IIa trial to evaluate single intravitreal injections of 1.5 mg QPI-1007 in about 60 patients with unilateral acute primary angle-closure glaucoma. RiboQuark -...
08:00 , Dec 19, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

BioSpring, Dr. Reddy's, InteRNA Technologies, Quiet Therapeutics, Laboratory of Pharmacology and Toxicology (LPT) GmbH & Co. KG, VU University Medical Center ca

The MIRacle Consortium received a €1.2 million ($1.6 million) grant from the EU's Framework Programme 7 (FP7) to develop tumor-selective microRNA-based therapeutics to treat head and neck cancer. The goal of the two-year consortium is...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Prosensa B.V., BioSpring, Institute of Myology, Leiden University Medical Center, Newcastle University musculoskeletal news

Prosensa said the Consortium for Products Across Europe in Duchenne Muscular Dystrophy (SCOPE-DMD) received a €6 million ($8 million) award from the EU's Seventh Framework Program (FP7) to support an ongoing Phase I/II trial of...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

QPI-1007: Phase I data

Interim data from an open-label, dose-escalation, international Phase I trial in 38 patients showed a single injection of QPI-1007 had no dose limiting toxicities up to and including the highest dose of 6 mg. The...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Clinical News

QPI-1007: Phase I started

Quark began an open-label, dose-escalation, U.S. and Israeli Phase I trial to evaluate intraocular QPI-1007 in legally blind patients and patients with recent onset NA-AION. Quark's QPI-1007 was developed in collaboration with BioSpring. BioSpring GmbH...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

BioSpring, Quark preclinical data

In a rat model of glaucoma, QPI-1007 administered 2 weeks after disease induction prevented retinal ganglion cell (RGC) loss, whereas RGC loss progressed in untreated controls. The siRNA against an undisclosed target was developed jointly...
07:00 , Jun 19, 2006 |  BC Week In Review  |  Company News

BioSpring, Genzyme, SR Pharma, OctoPlus B.V. deal

SPA's Atugen AG subsidiary partnered with GENZ, BioSpring and OctoPlus to manufacture Atugen's Atu027 siRNA therapeutic for cancer. GENZ will manufacture the product's lipid delivery system, BioSpring will produce the siRNA molecules, and OctoPlus is...
07:00 , Oct 5, 1998 |  BioCentury  |  Politics, Policy & Law

German biotech crosses party lines

German biotech crosses party lines StateGoverning parties # cos Leading lights Baden Wurttemberg Christian Democrat Union 37 LION bioscience, BASF-Lynx, BIG Biotech, CellGenix, Metabion N Rhine Westphalia Social Democrat/Green 28 Qiagen, Artemis, CardioGene, Greentech, NewLab...